BLLN BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About BillionToOne (NASDAQ: BLLN)
›
BillionToOne (NASDAQ: BLLN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 713 employees.
The shares were at 90.20 USD on 19 November 2026, down 9.2% over 52 weeks. Its 52-week range is 61.96 USD to 150.44 USD: the price is 40.0% below the high and 45.6% above the low.
At a market capitalisation of 4.31B USD, it trades at 98.0 times trailing earnings and 57.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a premium of 174% for BLLN.
BillionToOne reports return on equity of 1.6%, an operating margin of 10.2% and revenue up 47.2% year over year.
It holds more cash than debt, a net cash position of 421.06M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 128.29 USD is 42.2% above the current price. The next earnings report is expected on 3 March 2027.